Analystreport

Dicerna Pharmaceuticals (NASDAQ: DRNA) had its "hold" rating re-affirmed by analysts at HC Wainwright. They now have a $14.00 price target on the stock.

Dicerna Pharmaceuticals, Inc.  (DRNA) 
Last dicerna pharmaceuticals, inc. earnings: 2/27 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.dicerna.com